Download MendeleyStructure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.
Katz, J.D., Haidle, A., Childers, K.K., Zabierek, A.A., Jewell, J.P., Hou, Y., Altman, M.D., Szewczak, A., Chen, D., Harsch, A., Hayashi, M., Warren, L., Hutton, M., Nuthall, H., Su, H.P., Munshi, S., Stanton, M.G., Davies, I.W., Munoz, B., Northrup, A.(2017) Bioorg Med Chem Lett 27: 114-120
- PubMed: 27816515
- DOI: https://doi.org/10.1016/j.bmcl.2016.08.068
- Primary Citation of Related Structures:
5KZ7, 5KZ8 - PubMed Abstract:
The initial structure activity relationships around an isoindoline uHTS hit will be described. Information gleaned from ligand co-crystal structures allowed for rapid refinements in both MARK potency and kinase selectivity. These efforts allowed for the identification of a compound with properties suitable for use as an in vitro tool compound for validation studies on MARK as a viable target for Alzheimer's disease.
Organizational Affiliation:
Department of Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, USA. Electronic address: jason_katz2@merck.com.
